Aberrant purinergic signaling is believed to play a role in COPD pathogenesis. CD39 has ATPase activity and is hypothesized to be protective in cigarette smoke-induced lung damage. CD73 is the rate-limiting enzyme that breaks down AMP to adenosine (ADO), which in turn has anti-inflammatory effects. CD26 binds ADO deaminase which metabolizes ADO and can influence extracellular ADO levels.
Using flow cytometry, we evaluated differences in the expression of CD39, CD73, and CD26 on peripheral CD4+/CD8+ T cells among ART-treated HIV(+) and HIV(-) individuals with and without COPD [HIV(+)COPD(+) n=16; HIV(+)COPD(-) n=14; HIV(-)COPD(+) n=11; HIV(-COPD(-) n=12], and determined whether expression is associated with plasma levels of inosine (surrogate for ADO; INO) obtained by mass spectrometry and with pulmonary function testing (PFT; forced expiratory volume, FEV1; forced vital capacity; diffusing capacity).
With CD39 expression, HIV(-)COPD(+) had a trend for increased %CD4+CD39+ T cells compared to HIV(-)COPD(-) [12.7% vs 8.7, p=0.07; Kruskal-Wallis with Dunn’s post-test]. However, HIV(+)COPD(+) did not have higher %CD4+CD39+ T cells compared to HIV(+)COPD(-). There were no associations between CD39 expression and PFTs. With CD73 expression, HIV(+) participants with or without COPD, had lower %CD4+CD73+ [p values=0.004-0.006] and %CD8+CD73+ [p values=0.001-0.015] compared to all HIV(-) participants. In all participants with COPD, %CD8+CD73+ T cells significantly correlated with FEV1 (Spearman r=0.45, p=0.01). This correlation was not observed among all COPD(-) participants. Expression of CD39 or CD73 did not correlate with plasma INO levels. With CD26 expression, HIV(+)COPD(+) had lower %CD4+CD26+ than HIV(+)COPD(-) [p=0.035], HIV(-)COPD(+) [p=0.0005], and HIV(-)COPD(-) [p=0.02]. Similarly, %CD8+CD73+ was lower in the HIV(+)COPD(+) group compared to the HIV(-) groups, but similar to the HIV(+)COPD(-) group. In all participants, %CD4+CD26+ T cells modestly correlated with INO levels (r=0.25, p=0.09); among all COPD(+) participants, INO levels in turn, modestly correlated with FEV1 (r=0.35, p=0.06).
Compared to HIV(-)COPD(+) individuals, HIV(+)COPD(+) individuals do not have increased CD39 expression relative to HIV(+)COPD(-) individuals and have lower frequencies of CD4+ and CD8+ T cells expressing CD73 or CD26. Given these differences, COPD therapeutic strategies targeting the ADO signaling pathway may result in different outcomes for the HIV(+) population.